Lupin launches generic Wellbutrin XL® Tablets in the US

Wellbutrin XL® tablets had US sales of USD 758 million

Lupin Limited announced the launch of its Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg is the AB rated generic equivalent of Valeant Pharmaceuticals North America, LLC’s Wellbutrin XL® tablets, 150 mg and 300 mg. It is indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD) in adults.

Wellbutrin XL® tablets had US sales of USD 758 million (IMS MAT May 2017).